Pharming Group (NASDAQ:PHAR) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Pharming Group (NASDAQ:PHAR) issued its quarterly earnings results on Thursday. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.05, Zacks reports. The company had revenue of $97.30 million during the quarter, compared to analysts’ expectations of $98.22 million. Pharming Group had a net margin of 0.30% and a return on equity of 0.48%. Pharming Group updated its FY 2025 guidance to EPS.

Pharming Group Stock Performance

Shares of NASDAQ:PHAR opened at $15.43 on Friday. The company has a quick ratio of 2.07, a current ratio of 2.79 and a debt-to-equity ratio of 0.38. Pharming Group has a 12-month low of $7.31 and a 12-month high of $17.08. The company’s 50 day moving average price is $14.30 and its two-hundred day moving average price is $12.01. The firm has a market cap of $1.06 billion, a PE ratio of -1,541.46 and a beta of 0.03.

Institutional Trading of Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,979 shares of the company’s stock, valued at approximately $32,000. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PHAR has been the subject of several analyst reports. Weiss Ratings upgraded Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a report on Saturday, October 25th. Zacks Research raised Pharming Group from a “hold” rating to a “strong-buy” rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $30.00.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.